Gary Abromovitz
Nessuna posizione attualmente
Storia della carriera di Gary Abromovitz
Precedenti posizioni note di Gary Abromovitz
Società | Posizione | Inizio | Fine |
---|---|---|---|
HELEN OF TROY LIMITED | Direttore/Membro del Consiglio | 01/01/1990 | 24/08/2022 |
Independent Dir/Board Member | 01/01/1990 | 24/08/2022 | |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Direttore/Membro del Consiglio | 01/02/2005 | 10/08/2012 |
Independent Dir/Board Member | 01/02/2005 | 10/08/2012 |
Statistiche
Distribuzione geografica
Bermuda | 2 |
Stati Uniti | 2 |
Posizioni
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Settori
Consumer Durables | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
HELEN OF TROY LIMITED | Consumer Durables |
Aziende private | 1 |
---|---|
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
- Borsa valori
- Insiders
- Gary Abromovitz
- Esperienza